



FARADISE Registry:

Positive 12-month real-world results

One of the largest prospective FARAWAVE™ global registries

Favorable procedural and safety outcomes | Positive 12-month clinical effectiveness*

The FARADISE registry is a global, prospective study evaluating the real-world use of the FARAWAVE™ Pulsed Field Ablation Catheter with up to 3 years of patient follow-up.

- ▶ **48 Centers**
- ▶ **21 Countries** (Europe, Asia, Australia, Middle East)
- ▶ **1158 Patients** (65.0% PAF)

Ablation and monitoring protocols were implemented according to each hospital's standard of care.

SAFETY


1.5%

SERIOUS ADVERSE EVENT RATE
at 12 months

**No reported esophageal
fistulas or PV stenosis**

12-MONTH CLINICAL EFFECTIVENESS

Paroxysmal vs Non-Paroxysmal (PVI vs PVI+)



**Ablation strategy (PVI vs PVI+) had no impact on
12-month clinical effectiveness within AF indication**

LEARNING CURVE

More FARAWAVE experience led to:

- Greater **procedural efficiency**
- Increased PVI+ procedures

The **clinical effectiveness was consistent** across varying levels of device experience



PROCEDURAL INFORMATION

72.5% of all procedures had a PVI-only ablation strategy

- Procedure time = **51 min** [40, 70]
- LA dwell = **31 min** [24, 41]
- Fluoroscopy = **12 min** [8, 17]
(Median, IQR [Q1, Q3])

*Clinical effectiveness was defined as freedom from arrhythmia recurrence, repeat procedure, and cardioversion

1. Boersma, Real-World experience with the Pentaspline Pulsed Field Ablation System: One-year outcomes of the FARADISE Registry. ESC, 2025.

Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions at www.IFU-BSCI.com. Rx only. © 2025 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners. EP-2278301-AA